Glysantis Inc. to Present at the Biotech Showcase™ Annual Conference on January 10, 2018
Guelph, Jan 3, 2018 – Glysantis Inc. today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.
Ricky Ghoshal, Sr. Business Development Associate, will present at the Biotech Showcase™ as follows:
Date: Wednesday, January 10, 2018
Time: 10:30 am (PST)
Room: Hilton/Franciscan B
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
Glysantis will be showcasing its proprietary nanotechnology platform based on NanoDendrix™, a unique, monodisperse nanomaterial derived from corn. The company’s presentation will highlight selected applications of NanoDendrix™ nanoparticles in enhancing yields of viruses produced in cell culture as well as oligonucleotide delivery for gene therapies. Phil Whiting, CEO of Glysantis, said: “We are excited to be participating in the Biotech Showcase 2018 conference and look forward to introducing Glysantis for the first time and meeting potential investors and partners in San Francisco.” Glysantis will engage in partnering meetings with a focus on out-licensing and co-development of applications using NanoDendrix™.
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that Glysantis will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”
Glysantis Inc., a wholly-owned subsidiary of Mirexus Biotechnologies Inc. (MBI), is a biotechnology company active in pre-clinical research & development of an innovative nanoparticle technology platform, NanoDendrix, based on monodisperse nano-glycogen extracted from sweet corn. These naturally assembled nanoparticles are safe, non-toxic, fully biodegradable and can be chemically modified. Glysantis’ R&D efforts are developing applications in diverse areas such as immunomodulation and targeted drug delivery. Our scalable technology platform provides safe nanoparticles for a wide range of applications.
Company contact details:
Dr. Phil Whiting
Phone: +1 905 339 9907
Additional links and information: